RFA
CLDX icon

Reilly Financial Advisors’s Celldex Therapeutics CLDX Stock Holding History

Reilly Financial Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-7
Closed – – 926
2016
Q4 		$0 Hold
7
– – ﹤0.01% 843
2016
Q3 		$0 Hold
7
– – ﹤0.01% 841
2016
Q2 		$0 Buy
+7
New +$444 ﹤0.01% 831
2015
Q4 		– Sell
-7
Closed -$1.53K – 1234
2015
Q3 		$1K Sell
7
-19
-73% -$5.38K ﹤0.01% 1195
2015
Q2 		$10K Buy
26
+7
+37% +$2.78K ﹤0.01% 857
2015
Q1 		$8K Hold
19
– – ﹤0.01% 903
2014
Q4 		$5K Buy
+19
New +$4.72K ﹤0.01% 624

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KE
KLP Enterprises Branford, Connecticut $1.97M AUM
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Reilly Financial Advisors's CLDX Position: Q1 2017 in Review

Reilly Financial Advisors sold out of Celldex Therapeutics (CLDX) in Q1 2017, closing a stake of 7 shares.

Reilly Financial Advisors first reported a position in CLDX in Q4 2014 and held it in 7 quarters. The position peaked at $10K in Q2 2015. 134 funds tracked by Wall St. Rank hold CLDX as of Q1 2017.

  • Reilly Financial Advisors reported no remaining Celldex Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Reilly Financial Advisors sold 7 Celldex Therapeutics shares in Q1 2017.
  • Reilly Financial Advisors first reported a position in Celldex Therapeutics in Q4 2014 and held it in 7 quarters.
  • Reilly Financial Advisors's Celldex Therapeutics position peaked at $10K in Q2 2015.
  • 134 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2017.

Based on Reilly Financial Advisors's 13F filing for Q1 2017, filed 18 Apr 2017.